Key result
Ultrasound guided axillary vein access for CIED implantation had similar 30-day complications compared to conventional access (4% vs 7%; p=0.13) and reduced fluoroscopy time (4 vs 6 min; p<0.001).
Why the study?
Ultrasound guided axillary vein access is an emerging approach for CIED implantation that is not widely utilized.
Does ultrasound guided axillary vein access improve procedural metrics and safety compared to conventional access in patients undergoing CIED implantation?
Cohort (n=561)
Does ultrasound guided axillary vein access improve procedural metrics and safety compared to conventional access in patients undergoing CIED implantation?
Absolute Event Rate: 4% vs 7%
p-value: p=0.13
Ultrasound-guided axillary vein access before incision is a safe alternative for CIED implantation that reduces fluoroscopy time and may prevent unnecessary incisions.
UGAVA may shorten fluoroscopy with similar safety in CIED implantation; leaves open randomized confirmation before practice change.
Introduction Ultrasound guided axillary vein access (UGAVA) is an emerging approach for cardiac implantable electronic device (CIED) implantation not widely utilized. Methods and Results This is a retrospective, age and sex‐matched cohort study of CIED implantation from January 2017 to July 2019 comparing UGAVA before incision to venous access obtained after incision without ultrasound (conventional). The study population included 561 patients (187 with attempted UGAVA, 68 ± 13 years old, 43% women, body mass index (BMI) 30 ± 8 kg/m 2 , 15% right‐sided, 43% implantable cardioverter‐defibrillator, 15% upgrades). UGAVA was successful in 178/187 patients (95%). In nine patients where UGAVA was abandoned, the vein was too deep for access before incision. BMI was higher in abandoned patients than successful UGAVA (38 ± 6 vs. 28 ± 6 kg/m 2 , p < .0001). Median time from local anesthetic to completion of UGAVA was 7 min (interquartile range [IQR]: 4–10) and median procedure time 61 min (IQR: 50–92). UGAVA changed implant laterality in two patients (avoiding an extra incision in both) and could have prevented unnecessary incision in four conventional patients. Excluding device upgrades, there was reduced fluoroscopy time in UGAVA versus conventional (4 vs. 6 min; IQR: 2–5 vs. 4–9; p < .001). Thirty‐day complications were similar in UGAVA versus conventional ( n = 7 vs. 26, 4 vs. 7%; p = .13, p = .41 adjusting for upgrades), partly driven by a trend towards reduced pneumothorax ( n = 0 vs. 3, 0 vs. 1%; p = .22). Conclusions UGAVA is a safe approach for CIED implantation and helps prevent an extra incision if a barrier is identified changing laterality preincision.
No takes yet. Share an insight, caveat, or question.
Chandler et al. (2020) conducted a cohort in Cardiac implantable electronic device (CIED) implantation (n=561). Ultrasound guided axillary vein access (UGAVA) before incision vs. Venous access obtained after incision without ultrasound (conventional) was evaluated on Thirty-day complications (p=0.13). Ultrasound guided axillary vein access for CIED implantation had similar 30-day complications compared to conventional access (4% vs 7%; p=0.13) and reduced fluoroscopy time (4 vs 6 min; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: